NR2F6 deletion revives CAR-T cell function and induces antigen-agnostic immune memory in solid tumors

Area of Science:

• Immunology
• Oncology
• Gene Editing

Background:

• CAR-T cell therapy shows promise in blood cancers but faces challenges in solid tumors due to antigen variability and immune exhaustion.
• The tumor microenvironment often limits the effectiveness and persistence of CAR-T cells.

Purpose of the Study:

• To investigate the potential of gene editing the nuclear receptor NR2F6 to restore CAR-T cell functionality in solid tumors.
• To evaluate if NR2F6 inhibition can enhance CAR-T cell persistence, metabolic fitness, and cytotoxic potency against solid tumors.

Main Methods:

• Gene editing of the NR2F6 receptor in CAR-T cells.
• Assessment of CAR-T cell phenotype, metabolic fitness, and cytotoxic activity under chronic antigen exposure.
• Evaluation of CAR-T cell efficacy in immunocompetent solid tumor models, including tumor growth suppression and host immune responses.
• Analysis of tumor re-challenge protection and immune memory formation.

Main Results:

• NR2F6 gene editing sustained a progenitor-exhausted phenotype (TCF1⁺) in CAR-T cells, improving metabolic fitness and cytotoxic potency.
• Nr2f6-deficient CAR-T cells suppressed solid tumor growth in immunocompetent models.
• Durable tumor control was observed, persisting even after CAR-T cell clearance, associated with epitope spreading and secondary immune responses.
• Protection extended to antigen-negative tumors, indicating transferable immunity and a dual mechanism of direct cytotoxicity and immune reprogramming.

Conclusions:

• NR2F6 inhibition is a viable strategy to enhance CAR-T cell therapy for solid tumors by improving T cell function and overcoming immune exhaustion.
• This approach may lead to durable, antigen-agnostic immunotherapy by inducing broad host antitumor immunity, potentially mitigating immune escape.
• NR2F6 inhibition represents a promising avenue for engineering CAR-T cells for effective solid tumor treatment.